New segment model on human lung cancer
10 oktober, 2024
We are thrilled to launch our new model of Non-Small Cell Lung Cancer. We use patient-derived xenografts as well as mouse allografts to replicate clinical
We are thrilled to launch our new model of Non-Small Cell Lung Cancer. We use patient-derived xenografts as well as mouse allografts to replicate clinical
We proudly announce that IVRS AB has been appointed to Industry Winner 2024 within Biotechnical Research and Development! Branschvinnare i Sverige AB awards this title
We continue growing!
We are excited to launch our new orthotopic model of human glioblastoma. We use cutting-edge technology such as patient-derived xenografts (PDX) and in vivo bioluminescence
IVRS was recently appointed as industry winners or ‘’Branschvinnare’’, which is awarded to Swedish companies who have reached exceedingly positive revenue and result changes during the
We constantly work to develop clinically relevant models to provide reliable platforms for preclinical drug validation. Today, we are thrilled to announce the launch of
Do you want to learn more about our work and how we can help you?
Visit us
